5'-Azacitidine
Showing 26 - 50 of >10,000
Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia Trial
Recruiting
- Recurrent Chronic Myelomonocytic Leukemia
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Jul 21, 2022
MDS, Myeloproliferative Chronic Myelomonocytic Leukemia Trial in Houston (Cladribine, Cytarabine, Venetoclax)
Recruiting
- Myelodysplastic Syndromes
- Myeloproliferative Chronic Myelomonocytic Leukemia
- Cladribine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Oct 31, 2022
Acute Myeloid Leukemia Trial in Chicago (Azacitidine, Biospecimen Collection, Bone Marrow Aspirate)
Not yet recruiting
- Acute Myeloid Leukemia
- Azacitidine
- +5 more
-
Chicago, IllinoisNorthwestern University
Feb 16, 2023
Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in United States (Milademetan, AZA)
Terminated
- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome
-
Duarte, California
- +4 more
Sep 14, 2021
Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Recruiting
- Acute Bilineal Leukemia
- +8 more
- Azacitidine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jan 24, 2023
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Tumor Trial in Houston (Azacitidine, Quizartinib)
Recruiting
- Chronic Myelomonocytic Leukemia
- +5 more
-
Houston, TexasM D Anderson Cancer Center
May 23, 2022
Myeloproliferative Tumor Trial in Toronto (Azacitidine, Venetoclax)
Not yet recruiting
- Myeloproliferative Neoplasm
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Apr 12, 2022
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid
Active, not recruiting
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- +9 more
-
Sewell, New Jersey
- +4 more
Dec 13, 2022
Acute Myeloid Leukemia Trial in Los Angeles, San Francisco (Azacitidine, Tagraxofusp-erzs)
Not yet recruiting
- Acute Myeloid Leukemia
- Azacitidine
- Tagraxofusp-erzs
-
Los Angeles, California
- +1 more
Jan 31, 2023
Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation, Hematologic and Lymphocytic Disorder Trial in Houston (Azacitidine,
Recruiting
- Acute Myeloid Leukemia in Remission
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Dec 13, 2022
FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia Trial in Houston
Active, not recruiting
- FLT3 Gene Mutation Negative
- +7 more
- Azacitidine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Nov 16, 2022
Acute Myeloid Leukemia With Multilineage Dysplasia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Blasts 20-30 Percent of
Active, not recruiting
- Acute Myeloid Leukemia With Multilineage Dysplasia
- +6 more
- Azacitidine
- Glutaminase Inhibitor CB-839
-
Houston, TexasM D Anderson Cancer Center
Feb 25, 2022
Acute Myeloid Leukemia, MDS Trial in United States (SL-172154)
Recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
-
Duarte, California
- +12 more
Jan 23, 2023
Lymphoid Malignancies, Lymphoma, Hodgkin Lymphoma Trial in New York (Romidepsin, Oral 5-Azacitidine)
Terminated
- Lymphoid Malignancies
- +3 more
- Romidepsin
- Oral 5-Azacitidine
-
New York, New YorkColumbia University Medical Center
Jan 5, 2021
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Anti-OX40 Agonist Monoclonal Antibody
Active, not recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Anti-OX40 Agonist Monoclonal Antibody PF-04518600
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Jan 25, 2022
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells Trial in
Recruiting
- Acute Myeloid Leukemia
- +7 more
- Azacitidine
- +3 more
-
New Brunswick, New JerseyRutgers Cancer Institute of New Jersey
May 16, 2022
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Azacitidine,
Recruiting
- Acute Myeloid Leukemia
- +2 more
- Azacitidine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Nov 16, 2021
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia Trial in Los Angeles, Sacramento, Oklahoma City (Azacitidine,
Recruiting
- Acute Myeloid Leukemia
- Recurrent Acute Myeloid Leukemia
- Azacitidine
- +2 more
-
Los Angeles, California
- +2 more
Mar 11, 2022
Relapsed/Refractory Peripheral T-cell Lymphoma Trial in Suzhou (Anti-PD-1 mAb, Lenalidomide, Azacitidine)
Recruiting
- Relapsed/Refractory Peripheral T-cell Lymphoma
- Anti-PD-1 monoclonal antibody
- +2 more
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Dec 21, 2021
Acute Myeloid Leukemia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia Trial in Baltimore,
Active, not recruiting
- Acute Myeloid Leukemia
- +6 more
- Azacitidine
- +2 more
-
Baltimore, Maryland
- +2 more
Feb 25, 2022
Leukemia Trial in Houston (Brentuximab Vedotin, 5-Azacytidine)
Terminated
- Leukemia
- Brentuximab Vedotin
- 5-Azacytidine
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 7, 2022
Acute Myeloid Leukemia, MDS, Chronic Myelomonocytic Leukemia Trial in Canada, United States (CFI-400945, Azacitidine,
Recruiting
- Acute Myeloid Leukemia
- +5 more
- CFI-400945
- +2 more
-
Duarte, California
- +7 more
Jul 20, 2022
Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Trial in Houston (Azacitidine, Venetoclax)
Recruiting
- Acute Bilineal Leukemia
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Sep 30, 2021